|
For a complete list of Dr. Edwards' publications see below
Click here to download file
Articles in Multiple Sclerosis:
1. Cohen J, Calabresi P, Chakraborty S, Edwards K, Eickenhorst T , et. al, Avonex Combination Trial (ACT) in Relapsing-Remitting
MS. Rationale, Design, and Baseline Data Mult Scler 2008 Apr;14(3):370-382.
2. Phillips J,
Weinstock-Guttman B, Felton W, Englis J, Rossman H, Edwards K, Honeycutt W, Sheremata W.
A Multicenter, Open-label, Crossover Study of Safety, Tolerability, and Patient preference for a Single-Use Autoinjector
vs Manual Injection of Intramuscluar Interferon Beta-1a in Patients with Multiple Sclerosis. Inter Jour
of MS Care.: In Press
3.
Cohen J, Imrey P, Calabresi P, Edwards K, Eickenhorst T, Felton III W, Fisher E, Fox R,Goodman A, Hara-Cleaver C, Hutton G,
Mandell B, Scott T, Zang H, Apperson-Hansen C, Beck G, Houghtaling P, Karafa M, Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting
MS. Neurology 2009: 72;535-541
4. Glantz
M, Chamberlain M, Liu Q, Hsieh C, Edwards K, Horn A, Recht L. Gender disparity in the rate of partner abandonment in patients
with serious medical illness. Cancer 2009:115;5237-42
5.
Goodman A, Brown T, Edwards K, Krupp L, Schapiro R, Cohen R, Marinucci L, Blight A. A Confirmatory Phase 3 Trial of Sustained
Release Oral Fampridine in Multiple Sclerosis. Annals of Neurology 2010;68:494-502
6. Nielsen S, Miravalle A, Langer-Gould A, Cooper
J, Edwards K, Kinkel P. B cell depletion and safety of low dose rituximab in patients with relapsing multiple sclerosis. Multiple Sclerosis, 2012; 18: 277-378
7. Edwards K, Goodman W, Ma C. Improvement in neuropsycholological function in cognitively
impaired multiple sclerosis patients treated with natalizumab. Int. Journal of MS Care; 14:100-104
Articles in Alzheimer and Dementia:
1. Edwards KR, Hershey
L, WrayL, Bednarczyk EM, Lichter D, Johnson S. Efficacy and Safety of Galantamine
in Patients with Dementia with Lewy Bodies: A 12-Week Interim Analysis.
Dementia and Geriatric Cognitive Disorders 2004:17 (suppl 1) 40-48.
2. Sadowsky C, Edwards KR, Etemad B, Falow M. Maintaining effective treatment in
dementia: A case series on patients switched to rivastigmine. Primary Care Psychiatry 2004:9 71-75
3. Edwards KR, Koumaras B, Chen M, Gunay
I, Mirski D. Long-Term Effects of
Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s
Disease: Results of a 52-Week Open-Label Study Clinical Drug Investigation 2005: 25 507-515.
4. Grossberg G, Edwards K, Zhao Q. Galantamine with Adjunctive memantine: Combined Effects on Brain Nicotinic Acetylcholine
Receptors and N-methyl-D aspartate (NMDA) Receptors may Improve Alzheimer’s Disease Symptomatology J. Clin. Pharmacol 2006 46: 17S - 26S.
5. Bhasin M, Rowan E. Edwards K, McKeith IG. Cholinesterase inhibitors
in Dementia with Lewy Bodies – A comparative analysis. Int J Ger Psychiatry 2007: 22; 890 – 895
6. Edwards K, Royall D, Hershey L, Lichter
D, Hake A, Farlow M Pasquier F, Johnson S. Efficacy and Safety of Galantamine
in Patients with Dementia with Lewy Bodies: A 24-Week Open Label Study. Dem Ger Cog Dis. 23: 301-305, 2007
7. Connor G, Edwards K, Tarsy D. Topiramate in Essential Tremor: Findings from Double-Blind, Placebo-Controlled, Crossover Trials. Clin Neuropharmacol 2008 Mar-Apr;31(2):97-103
.
|
